Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2025-02-12 Earnings Release
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Earnings Release 2024
Earnings Release Classification · 98% confidence The document is titled "Q4.2024 Bokslutskommuniké januari – december 2024" (Year-end Report/Communication January – December 2024) and contains a detailed financial overview table covering the fourth quarter and the full year (januari – december 2024), including Net Sales, Operating Result, and Cash Flow. It also includes a CEO's statement summarizing the year's progress and a financial calendar listing future reports, including the "Årsredovisning 2024" (Annual Report) release date. The content is a comprehensive summary of annual financial performance and operational highlights, which aligns perfectly with the definition of an Annual Report (10-K) or a comprehensive year-end financial communication. Since it provides the full year's financial summary and is explicitly called a 'Bokslutskommuniké' (Year-end Communication), it is classified as the primary annual financial disclosure. Although it is not explicitly labeled '10-K' (which is the SEC filing name), in a global context, a comprehensive year-end financial report is best categorized as 10-K, as it covers the full fiscal year performance, distinguishing it from a quarterly report (IR). The document length is substantial (73,585 chars), confirming it is the report itself, not just an announcement of a report (RPA). Q4 2024
2025-02-12 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q4.2024 Year-end report January – December 2024' and contains comprehensive financial tables (Net sales, Operating profit, Cash flow, etc.) for the period ending December 2024. It includes detailed management commentary, R&D updates, and a financial summary. As it provides substantive financial data and analysis for a period shorter than a full fiscal year (Q4/Full-year), it is classified as an Interim/Quarterly Report. Q4 2024
2025-02-12 English
Valberedningen utsedd inför IRLAB:s årsstämma 2025
AGM Information Classification · 95% confidence The document is a press release from IRLAB Therapeutics AB, dated November 21, 2024, announcing the appointment of the members of the Nomination Committee (Valberedningen) for the upcoming Annual General Meeting (AGM) in 2025. This announcement concerns the composition of the committee responsible for proposing board members and auditors for the AGM. While it relates to the AGM, the core content is the announcement of the committee's composition and the process for shareholder proposals, which falls under corporate governance and preparatory materials for the AGM. The closest specific category is 'AGM Information' (AGM-R), as it directly pertains to the preparation and structure surrounding the Annual General Meeting. It is not a proxy statement (PSI) or a declaration of voting results (DVA), but rather a preparatory announcement regarding the AGM's governance structure.
2024-11-21 Swedish
Nomination committee appointed for IRLAB’s annual general meeting 2025
Board/Management Information Classification · 99% confidence The document explicitly discusses the appointment of the nomination committee ahead of the 'annual general meeting (AGM) 2025'. This content directly relates to the governance and preparation for the AGM. While it is an announcement, the subject matter is specifically about the AGM structure and process, which aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, and by extension, the preparatory steps like committee appointments. It is not a general regulatory filing (RNS) or a proxy statement (PSI), as it focuses on the committee composition rather than soliciting votes or providing full proxy details.
2024-11-21 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for IRLAB Therapeutics AB covering the period January to September 2024. It contains detailed financial tables (income statement, cash flow, etc.), management commentary, and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-10-30 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q3.2024 Interim report January – September 2024' and contains comprehensive financial summaries, including net sales, operating profit, and cash flow for the specified period. It also includes detailed management commentary, R&D updates, and strategic priorities. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2024
2024-10-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.